Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor

Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor

Kimberly A Redic,1 Shannon M Hough,2 Erika M Price11College of Pharmacy, University of Michigan, 2Department of Pharmaceutical Services, University of Michigan Health System, Ann Arbor, MI, USABackground: Panobinostat is a new agent for the treatment of relapsed and refractory multiple myeloma (rrMM...

Full description

Bibliographic Details
Main Authors: Redic KA, Hough SM, Price EM
Format: Article
Language:English
Published: Dove Medical Press 2016-05-01
Series:OncoTargets and Therapy
Subjects:
Panobinostat
Multiple Myeloma
LBH589
Online Access:https://www.dovepress.com/clinical-developments-in-the-treatment-of-relapsed-or-relapsed-and-ref-peer-reviewed-article-OTT

Internet

https://www.dovepress.com/clinical-developments-in-the-treatment-of-relapsed-or-relapsed-and-ref-peer-reviewed-article-OTT

Similar Items